Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma.

Trial Profile

Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 30 Nov 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 01 Dec 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top